Compound library screening in drug discovery aims to identify a compound or a series of compounds that can bind to the drug target and modulate its activity. Here, we discuss weak affinity chromatography (WAC™), the proprietary fragment screening technique jointly owned by SARomics Biostructures and Red Glead Discovery.
Looking back and analyzing our experience, the question we discuss here is, what makes a successful services company? What is our strength, and how to define our selling points? We arrive at a list of 8 essential selling points defining the success of SARomics Biostructures.
A fantastic year for the company!
New team members, and new services, including WAC fragments screening and characterization of higher-order structure of biosimilars, were introduced, and many new customers found their way to us!